Aller au contenu principal
2026 conference-abstract

Abstract 7665: Multi-step antibody validation for nCounter high-plex multiomics panels.

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract Expanded development on the nCounter® Analysis System now enables simultaneous quantification of over 500 proteins and up to 800 transcripts from a single FFPE tissue sample. With the introduction of two high-plex protein panels used in combination with any prebuilt nCounter® RNA Panel this new capability brings a novel non-destructive FFPE assay with new depth, simplicity and reliability for immuno-oncology multiomics research. The nCounter® platform has long been known as the gold standard for oncology and immunology studies including diagnostic development. Confirming performance in support of translational and clinical applications is essential part of this capabilityTo ensure high data integrity in this complex environment, we developed a rigorous multi-step antibody validation pipeline. The process begins with an initial IHC screening, performed by our antibody partner AbCam, to confirm specificity in known positive and negative tissues. These single-plex IHC validated antibodies are individually conjugated to nCounter-compatible UV-cleavable oligonucleotides. Functional performance of the high-plex protein panels was assessed using more than 90 cell lines and more than 100 tissue cores from over 30 tissue types featuring cancerous and healthy FFPE samples. Sensitivity and specificity are benchmarked against available orthogonal RNA-Seq and mass spectrometry datasets for the cell lines. The specificity of phospho-specific antibodies was also tested in a phosphatase treatment assay, confirming that >90% of signal is reduced with treatment.To demonstrate the compatibility of these antibodies in a high-plex panel, we show antibody performance remains robust when our protein panels are stacked together or run independently. Finally, reproducibility is confirmed across users and runs. This validation framework ensures high specificity, sensitivity, and reproducibility, enabling confident multiomic profiling of complex tissue samples and accelerating translational insights in cancer biology. Citation Format: Giang Ong, Terence C. Theisen, Brian Filanoski, Lori Hamanishi, Erin Piazza, Christina Bailey, Prajan Divakar, Margaret L. Hoang, Joseph M. Beechem, . Multi-step antibody validation for nCounter high-plex multiomics panels [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7665.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Abstract 7665: Multi-step antibody validation for nCounter high-plex multiomics panels.
Date Crossref
03/04/2026
Éditeur
American Association for Cancer Research (AACR)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Advanced Biosensing Techniques and ApplicationsSingle-cell and spatial transcriptomicsAdvanced Proteomics Techniques and Applications

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.